CatalystFDA/Bio

UroGen gets FDA review for new bladder cancer therapy

FDA review milestone for new bladder cancer therapy drives high relevance.

What changed

FDA review milestone for new bladder cancer therapy drives high relevance.

Why it matters

FDA review milestone for new bladder cancer therapy drives high relevance. — impact context not separately stored; see What changed.

Sources